Jazz Pharmaceuticals plc (J7Z) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jazz Pharmaceuticals plc (J7Z) has a cash flow conversion efficiency ratio of 0.090x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€408.20 Million ≈ $477.23 Million USD) by net assets (€4.53 Billion ≈ $5.30 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Jazz Pharmaceuticals plc market capitalisation for the company's overall valuation and market capitalisation.
Jazz Pharmaceuticals plc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Jazz Pharmaceuticals plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jazz Pharmaceuticals plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jazz Pharmaceuticals plc ranked by their cash flow conversion efficiency. Explore J7Z cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
S-Oil Corp
KO:010950
|
0.209x |
|
Shannon Semiconductor Technology Co Ltd
SHE:300475
|
-0.031x |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
-0.221x |
|
Pro Medicus Ltd
AU:PME
|
0.149x |
|
Dynatrace Holdings LLC
NYSE:DT
|
0.086x |
|
Ningbo Tuopu Group Co Ltd
SHG:601689
|
0.062x |
|
Bank of Chengdu Co Ltd
SHG:601838
|
-0.135x |
|
Krung Thai Bank Public Company Limited
F:NVPB
|
0.153x |
Annual Cash Flow Conversion Efficiency for Jazz Pharmaceuticals plc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Jazz Pharmaceuticals plc from 2013 to 2025. View J7Z stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.32 Billion ≈ $5.05 Billion |
€1.36 Billion ≈ $1.59 Billion |
0.314x | -7.93% |
| 2024-12-31 | €4.09 Billion ≈ $4.79 Billion |
€1.40 Billion ≈ $1.63 Billion |
0.341x | +16.69% |
| 2023-12-31 | €3.74 Billion ≈ $4.37 Billion |
€1.09 Billion ≈ $1.28 Billion |
0.292x | -29.11% |
| 2022-12-31 | €3.09 Billion ≈ $3.61 Billion |
€1.27 Billion ≈ $1.49 Billion |
0.412x | +109.95% |
| 2021-12-31 | €3.97 Billion ≈ $4.64 Billion |
€778.51 Million ≈ $910.16 Million |
0.196x | -20.13% |
| 2020-12-31 | €3.66 Billion ≈ $4.28 Billion |
€899.65 Million ≈ $1.05 Billion |
0.246x | -1.50% |
| 2019-12-31 | €3.11 Billion ≈ $3.64 Billion |
€776.40 Million ≈ $907.69 Million |
0.250x | -13.86% |
| 2018-12-31 | €2.76 Billion ≈ $3.22 Billion |
€798.90 Million ≈ $934.00 Million |
0.290x | +13.41% |
| 2017-12-31 | €2.71 Billion ≈ $3.17 Billion |
€693.09 Million ≈ $810.29 Million |
0.255x | -19.04% |
| 2016-12-31 | €1.88 Billion ≈ $2.19 Billion |
€592.39 Million ≈ $692.57 Million |
0.316x | -5.17% |
| 2015-12-31 | €1.60 Billion ≈ $1.87 Billion |
€531.94 Million ≈ $621.90 Million |
0.333x | +11.94% |
| 2014-12-31 | €1.37 Billion ≈ $1.60 Billion |
€407.61 Million ≈ $476.53 Million |
0.297x | +33.52% |
| 2013-12-31 | €1.30 Billion ≈ $1.51 Billion |
€288.43 Million ≈ $337.21 Million |
0.223x | -- |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more